Multiple law firms have filed a securities class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO), alleging that the company defrauded investors by downplaying and concealing significant safety concerns related to its hyperphagia drug DCCR, branded as VYKAT™ XR. Investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, are eligible to participate in the class action, which was triggered when the company disclosed disappointing clinical trial information on November 5, 2025, causing the stock price to plummet 26% in a single day.
The lawsuit alleges that Soleno made misrepresentations and failed to adequately disclose evidence of excess fluid retention in clinical trial participants, and that the company may have conducted sham clinical trials to support the drug’s approval. This article explains what happened, why investors are suing, the safety concerns at the center of the dispute, and what steps investors can take to protect their interests. The broader context matters here: an activist short seller, Scorpion Capital, raised initial questions about Soleno’s disclosures in August 2025, and the stock had already declined approximately 40% from mid-August through early November before the company’s November announcement. This pattern—early warning signs followed by a significant stock price collapse when the truth emerged—is typical of securities fraud cases where companies allegedly concealed material information from investors.
Table of Contents
- What Are the Core Allegations Against Soleno Therapeutics?
- The Timeline of Events and Warning Signs
- The Medical and Commercial Context of the Drug
- How Investors Can Participate in the Class Action
- The Broader Implications for Biotech Investor Oversight
- Comparing This Case to Other Biotech Fraud Settlements
- What Comes Next in the Legal Process
What Are the Core Allegations Against Soleno Therapeutics?
The class action complaint centers on allegations that soleno Therapeutics deliberately downplayed, misrepresented, and/or concealed significant evidence of safety concerns related to DCCR, a drug intended to treat hyperphagia (excessive hunger) in individuals with Prader-Willi Syndrome (PWS). Specifically, the lawsuit alleges that the company concealed evidence of excess fluid retention in clinical trial participants and may have conducted what plaintiffs characterize as sham clinical trials. These are serious allegations because they suggest the company knew about safety issues but chose not to disclose them to investors, thereby misleading the market about the drug’s viability and the company’s prospects.
The significance of these allegations becomes clear when you consider Soleno’s position as a relatively small pharmaceutical company heavily dependent on VYKAT™ XR’s commercial success. If the drug has unresolved safety issues, it could face regulatory setbacks, market rejections, or mandatory modifications—any of which would substantially impact the company’s value. By allegedly concealing these issues, the company may have allowed investors to continue buying the stock at inflated prices based on incomplete information. Once the truth emerged on November 5, 2025, when the company reported disappointing information about DCCR, the stock market repriced the company’s value downward, and investors who purchased shares during the class period suffered losses.
The Timeline of Events and Warning Signs
Understanding when information became available to the market is critical in securities fraud cases. The activist short seller Scorpion Capital published a report on August 15, 2025, raising questions about Soleno’s disclosures and the adequacy of the company’s clinical trial data. This event marked the beginning of a significant decline in Soleno’s stock price; from August 14, 2025, through November 5, 2025, the stock fell approximately 40%. However, this initial warning sign did not immediately trigger a massive stock collapse, suggesting that many investors either were unaware of Scorpion Capital’s concerns or did not find them fully credible.
The real turning point came on November 5, 2025, when Soleno itself disclosed disappointing information about DCCR. On that day alone, the stock dropped 26%, confirming that the market had been operating under incomplete information. For investors who purchased shares during the March-to-November window, this created a significant gap between what they thought they were buying and what the company’s actual prospects turned out to be. The class period was defined to capture all investors who purchased during this window of alleged concealment, from March 26, 2025, through November 4, 2025. This distinction matters: investors who bought before March 26, 2025, or after November 4, 2025, would not be part of the class because the alleged fraud either hadn’t occurred yet or had already been disclosed.
The Medical and Commercial Context of the Drug
DCCR (VYKAT™ XR) was being developed to address hyperphagia, a condition characterized by severe, uncontrollable hunger that is particularly prevalent in individuals with Prader-Willi Syndrome. PWS is a rare genetic disorder affecting approximately 1 in 15,000 births, and hyperphagia is one of its most challenging symptoms. For affected individuals and families, an effective treatment could be genuinely life-changing, which is why investors were presumably interested in Soleno’s prospects. The company was positioned to be a niche player in an underserved market, and commercial success with VYKAT™ XR could have substantially increased the company’s market value and revenue.
However, the allegations suggest that the company’s approach to demonstrating safety and efficacy may not have been as rigorous as represented to investors. If clinical trial participants experienced excess fluid retention—a potentially serious side effect—that information should have been prominently disclosed to the FDA, to prospective patients, and to investors. The fact that Soleno allegedly concealed or downplayed this concern suggests the company may have prioritized getting the drug to market over ensuring patient safety and maintaining transparent communication with the investment community. This is a cautionary tale about how even drugs targeting small, underserved populations require the highest standards of honesty and rigor; cutting corners on safety reporting puts patients and investors alike at risk.
How Investors Can Participate in the Class Action
If you purchased Soleno Therapeutics common stock (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, you may be eligible to participate in this securities class action. The lead plaintiff filing deadline is May 5, 2026, which means investors have a limited window to consider their options and take action. There are generally two paths: you can either wait to see if you are automatically included in a settlement if one is reached, or you can actively submit a claim to recover losses.
To participate, you will need documentation of your stock purchases and sales during the class period, including confirmation statements, brokerage records, or tax documents showing the dates, quantities, and prices of your transactions. The law firms handling the case—including Hagens Berman, Kessler Topaz Meltzer & Check, Levi & Korsinsky, and Kahn Swick & Foti—can review your purchase history and estimate potential losses. participating in the class action does not require you to pay anything upfront; the attorneys typically work on a contingency fee basis, meaning they are paid only if the case settles or wins at trial. However, if you have losses during the class period, you should contact one of the firms representing the class as soon as possible to ensure your interests are protected, especially as the May 5, 2026, deadline approaches.
The Broader Implications for Biotech Investor Oversight
This case highlights an ongoing tension in biotech investing: companies developing drugs in niche therapeutic areas often receive heightened investor attention and optimism, sometimes at the expense of appropriate scrutiny. Soleno’s stock likely benefited from investor enthusiasm about VYKAT™ XR as a potential breakthrough treatment for hyperphagia in PWS, a condition for which treatment options are limited. However, the lawsuit suggests that this enthusiasm was not matched by corresponding honesty about clinical trial results and safety signals. One important warning: not every disappointing clinical trial outcome or safety issue results in a fraud lawsuit.
The key difference in this case is that the allegations specifically focus on the company’s concealment of information it allegedly knew or should have known. The short seller report in August 2025 suggests that questions about Soleno’s disclosures were circulating in the market, but many investors apparently did not believe or act on them until the company itself disclosed disappointing information in November. This pattern—where early warning signs are ignored until official company statements confirm concerns—is unfortunately common in securities fraud cases. Investors should be wary of companies that make bold claims about drug candidates without acknowledging limitations in the underlying clinical data, and they should pay attention when independent voices, such as activist short sellers, raise specific technical questions.
Comparing This Case to Other Biotech Fraud Settlements
The Soleno case follows a familiar pattern seen in other biotech fraud lawsuits: a company makes optimistic public statements about a drug’s potential, investors buy the stock, clinical or regulatory problems emerge, the stock crashes, and a class action lawsuit follows. These cases typically settle for substantial sums—ranging from millions to hundreds of millions of dollars depending on the size of investor losses and the strength of the evidence. For example, investors who purchased during the alleged fraud period in Soleno’s case lost approximately 40% of their investment value through November 5, 2025, and potentially more after that date. When multiplied across all shareholders who held the stock during the class period, these losses can aggregate to significant numbers that support a substantial settlement.
However, it’s important to understand that settlement amounts are typically only a fraction of actual investor losses. If you lost $10,000 on Soleno shares purchased during the class period, a settlement might recover 20% to 40% of that loss, depending on the final settlement amount and the number of claims filed. The recovery is not guaranteed; it depends on whether the defendants choose to settle or proceed to trial, and if they settle, what amount they agree to pay. Nonetheless, participating in the class action is generally the most practical way for individual investors to recover any portion of their losses, since pursuing individual litigation against a company with substantial legal resources would be prohibitively expensive.
What Comes Next in the Legal Process
The May 5, 2026, deadline is a critical threshold: once the lead plaintiff is appointed, the class action will move into the discovery phase, where both sides will exchange documents, take depositions, and build their cases. For investors, this means the next several months are when you should focus on gathering your records and contacting one of the law firms handling the case to register your claim. After the lead plaintiff is appointed, the case will likely proceed toward either a settlement negotiation or trial, a process that typically takes six months to two years.
Looking ahead, the Soleno case will likely serve as another data point for biotech investors and regulators about the importance of strong clinical trial oversight and transparent reporting of safety data. The FDA and other regulatory bodies may use this case to reinforce guidance about when and how companies must disclose safety concerns to the public and to investors. For Soleno itself, the company will need to navigate not only the class action but also potential regulatory scrutiny of its clinical trial practices and the future development of VYKAT™ XR. Whether the company can survive this reputational and financial blow, or whether it becomes another cautionary tale in biotech, will become clearer as the litigation and regulatory process unfolds.